The Global Alzheimer’s Therapeutics Industry is experiencing a momentous ascent, reaching an estimated valuation of US$ 3,052.3 million in 2023, according to a recent study by Future Market Insights (FMI). Projections indicate a robust growth trend, with demand expected to surge at a Compound Annual Growth Rate (CAGR) of 9.2%. By the year 2033, the market is anticipated to achieve a substantial US$ 7,359.7 million, marking a significant expansion that underscores the industry’s dedication to finding effective treatments and interventions for Alzheimer’s.
The increasing prevalence of Alzheimer’s and the commitment to addressing its impact on individuals and healthcare systems worldwide are driving this impressive growth. Population aging across the globe stands out as a major contributing factor, with rising life expectancy leading to significant increases in the number of the aged population.
Request a Sample Copy of the Report Now.
https://www.futuremarketinsights.com/reports/sample/rep-gb-14497
Therapies for Alzheimer’s therapeutics offer temporary and uncertain improvements in the well-being of individuals, and none of the approved drugs can modify the course of the disease Alzheimer’s Therapeutics cement. Thus, the magnitude of the affected population and the lack of suitable and effective treatment offers an incredible opportunity for drug manufacturers.
However, the identification of the primary reasons and mechanisms involved in Alzheimer’s therapeutics is limited. Drug manufacturers have been unable to validate the significant clinical benefits of treatment for numerous new compounds due to strict regulations. One of the significant trends observed in this market is the collaboration of the existing players.
Precisely, diagnostic technology companies are carefully trying to bring about effective biomarker technologies to support and improve the drug development process for potential drug candidates, which is further expected to propel the demand.
Developing countries are expected to offer lucrative opportunities for this market. According to Alzheimer’s Therapeutics International in 2015, 58% of people with dementia live in developing countries, but by 2050 this will rise to 68%. The fastest growth in the elderly population is taking place in China, India, and their South Asian and Western Pacific region.
According to the World Alzheimer Report in 2015, regional estimations of dementia prevalence in people aged 60 years and over vary from 4.6% in Central Europe to 8.7% in North Africa and the Middle East, however, all other regional estimates fall in relatively between 5.6% and 7.6%.
Discovering the assumptions behind the study. Speak to our Research Expert
https://www.futuremarketinsights.com/ask-question/rep-gb-14497
Top 17 Key Players Covered in the Global Alzheimer’s Therapeutics Industry are:
- AbbVie, Inc.
- Teva Pharmaceuticals Ltd.
- Eisai Co., Ltd.
- Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
- Novartis AG
- Zydus Lifesciences Ltd (CADILA)
- Sun Pharmaceutical Industries Ltd.
- Dr. Reddy’s Laboratories Ltd
- Aurobindo Pharma Ltd
- Amneal Pharmaceuticals Inc.
- Macleods Pharmaceuticals Ltd.
- Viatris Inc.
- Lupin Ltd
- Cipla Ltd.
- Torrent Pharmaceuticals Ltd.
- Unichem laboratories ltd
- Lannett Inc.
Access Exclusive Market Insights – Purchase Now!
https://www.futuremarketinsights.com/checkout/14497
Key Segments Covered in Global Alzheimer’s Therapeutics Industry Research
By Drug Name:
- Donepezil
- Rivastigmine
- Memantine
- Galantamine
- Manufactured a combination of memantine and donepezil
By Drug Class:
- Cholinesterase Inhibitors
- NMDA Receptor Antagonists
- Manufactured Combination
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
Comments
0 comment